Bamco Inc. NY Has $34.69 Million Stock Holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Bamco Inc. NY grew its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 53.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 752,886 shares of the company's stock after acquiring an additional 263,500 shares during the quarter. Bamco Inc. NY owned 2.69% of Establishment Labs worth $34,685,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in ESTA. Capital Research Global Investors increased its stake in shares of Establishment Labs by 29.3% during the 4th quarter. Capital Research Global Investors now owns 1,911,525 shares of the company's stock worth $88,064,000 after purchasing an additional 433,484 shares during the last quarter. Voya Investment Management LLC raised its holdings in Establishment Labs by 7,249.5% in the 4th quarter. Voya Investment Management LLC now owns 408,262 shares of the company's stock valued at $18,809,000 after acquiring an additional 402,707 shares during the period. Assenagon Asset Management S.A. bought a new stake in shares of Establishment Labs during the fourth quarter worth approximately $12,898,000. William Blair Investment Management LLC lifted its holdings in Establishment Labs by 44.1% during the 4th quarter. William Blair Investment Management LLC now owns 812,825 shares of the company's stock worth $37,447,000 after purchasing an additional 248,888 shares during the last quarter. Finally, Boothbay Fund Management LLC boosted its position in shares of Establishment Labs by 68.8% in the fourth quarter. Boothbay Fund Management LLC now owns 525,248 shares of the company's stock valued at $24,198,000 after acquiring an additional 214,119 shares during the period. 72.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on ESTA. Stephens restated an "overweight" rating and issued a $52.00 price target on shares of Establishment Labs in a research report on Thursday, March 6th. Needham & Company LLC assumed coverage on shares of Establishment Labs in a research report on Monday, April 14th. They set a "hold" rating on the stock. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $57.40.

Establishment Labs Price Performance

Shares of NASDAQ ESTA traded down $0.79 during midday trading on Friday, reaching $34.01. 485,256 shares of the company were exchanged, compared to its average volume of 466,896. Establishment Labs Holdings Inc. has a one year low of $26.56 and a one year high of $60.12. The stock has a market cap of $981.05 million, a P/E ratio of -13.18 and a beta of 0.73. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. The stock's 50-day moving average price is $34.83 and its 200-day moving average price is $38.52.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.13. The business had revenue of $41.38 million during the quarter, compared to analysts' expectations of $41.15 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The business's revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.58) EPS. On average, sell-side analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.